• The loss of synaptic proteins such as synaptophysin

  2024-04-15

  

  The loss of synaptic proteins such as synaptophysin from the Chlorogenic acid is indicative of synapse degeneration and provided a good correlate of the degree of dementia in AD [12], [13], [14]. Consequently, the loss of synaptic proteins from cultured primary neurons incubated with Aβ provides a

• br Acknowledgement br Introduction There

  2024-04-13

  

  Acknowledgement Introduction There has been great progress in the treatment of autoimmune disease during the past several decades. However, the majority of autoimmune diseases have no known cure. B lymphocytes and autoantibodies play important roles in many autoimmune diseases, including rheum

• br Materials and Methods br Results br Discussion XHP is

  2024-04-12

  

  Materials and Methods Results Discussion XHP is a traditional Chinese anti-cancer medicine that is widely used for the treatment and adjuvant treatment of breast cancer. XHP has been shown to induce apoptosis in various breast cancer perk inhibitor in vitro, including Hs578T, MCF-7, and MD

• fostamatinib The first evidence in supporting the hypothesis

  2024-04-12

  

  The first evidence in supporting the hypothesis that MAS receptors mediate the effects elicited by AT1 antagonists was provided by Iwai et al. (2012). The authors found that AT1 receptors triggers neointima formation after polyethylene-cuff placement around mouse femoral artery by reducing local ACE

• The excellent safety profile of solanezumab and encouraging

  2024-04-12

  

  The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr

• In our previous study we found that the total activity

  2024-04-12

  

  In our previous study we found that the total activity of aldehyde dehydrogenase in cancer EG00229 of RCC is at the same level as in normal renal tissue [10]. These findings are similar to our results in serum patients with renal cancer. There is no significant difference between ALDH activity in se

• Besides its multiple peripheral effects adiponectin may amel

  2024-04-12

  

  Besides its multiple peripheral effects adiponectin may ameliorate insulin resistance by acting in the brain, and intracerebroventricular administration of adiponectin in rodents decreases body weight by stimulating energy expenditure [13]. Adiponectin most likely crosses the blood-CSF-barrier (BCB)

• AG-14361 Since forskolin is known to

  2024-04-12

  

  Since forskolin is known to act directly at the catalytic site of adenylate cyclases near the ATP binding (Tesmer et al., 1997), the synergistic and/or permissive effect of gonadotropins on FSK activity must occur at the level of AC itself or very near, at the level of one of its direct partner. The

• A more versatile cellular delivery system for

  2024-04-12

  

  A more versatile cellular delivery system for adenosine was generated by engineering mouse embryonic stem cells to lack both Indomethacin of Adk (Fedele et al., 2004). Using a step-wise differentiation protocol (Okabe et al., 1996) Adk−/− ES cells were differentiated into transplantable adenosine-r

• br Cytochrome b br Cytochrome P hydroxylase lyase P

  2024-04-11

  

  Cytochrome b5 Cytochrome P450 17α-hydroxylase/17,20-lyase (P450 17A1) A number of P450s involved in steroid biosynthesis are multifunctional as they carry out two or more sequential hydroxylation reactions on the same substrate(s). P450 17A1 is a dual function endoplasmic reticulum enzyme enco

• Earlier studies showed that exposure

  2024-04-11

  

  Earlier studies showed that exposure of cells to IR caused ATM-dependent phosphorylation of 53BP1, as judged by electrophoretic mobility shift [24], [25], [26]. To date, the only known in vivo 53BP1 phosphorylation site(s) are Ser25 and possibly Ser29 [27]. In the course of our studies, we noticed t

• A phase I trial has recently evaluated enzalutamide

  2024-04-11

  

  A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with

• br Acknowledgements This work was supported by Programme Gra

  2024-04-11

  

  Acknowledgements This work was supported by Programme Grants from the MRC and the Wellcome Trust (SGC-C and MF). CB was in receipt of a Marie Curie Intra-European Fellowship during part of this work. We thank past and present members of our group for numerous valuable discussions throughout these

• bosentan Similarly compound was prepared from aldehyde d by

  2024-04-11

  

  Similarly, bosentan 13 was prepared from aldehyde 8d by following similar procedures (Scheme 3). Condensation of 13 with 7b or 7e provided the corresponding amides 9j or 9k, which then went through O-debenzylation by BCl3 to deliver the final compounds 10j and 10k in 37% and 32% overall yields, resp

• To further demonstrate the significance of Nrf

  2024-04-11

  

  To further demonstrate the significance of Nrf2 activation in the prevention of EGF-induced CRC growth by AR inhibitor, we examined the effect of fidarestat on EGF-induced cell viability in Nrf2-ablated cells. Our results suggest that AR inhibitor prevented the EGF-induced cell viability in control

14365 records 108/958 page Previous Next First page 上5页 106107108109110 下5页 Last page